Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD [Seeking Alpha]
Regulus Therapeutics Inc. (RGLS)
Last regulus therapeutics inc. earnings: 3/12 04:37 pm
Check Earnings Report
US:NASDAQ Investor Relations:
regulusrx.com/investors
Company Research
Source: Seeking Alpha
Additional results from cohort 3 of phase 1b study, using RGLS8429 for patients with ADPKD, expected in mid-2024; Higher dose of 3 mg/kg of drug being deployed for this cohort. Highly positive Type D meeting held with FDA and stated that a single phase 2 study could be used for an Accelerated Approval of RGLS8429 for ADPKD. Completion of an oversubscribed $100 million private placement agreement will give it a cash runway into the 1st half of 2026. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Regulus Therapeutics Inc. NASDAQ: RGLS ) is advancing the use of its drug RGLS8429 for the treatment of patients with autosomal dominant polycystic kidney disease [ADPKD] in an ongoing phase 1b study. It recently reported positive results from cohort 2 of this study using this drug to treat this patient population. Why I believe that investors might benefit from looking into this
Show less
Read more
Impact Snapshot
Event Time:
RGLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGLS alerts
High impacting Regulus Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
RGLS
News
- Global Antisense and RNAi Therapeutics Report 2024: A USD 34.7 Billion Predicted Market by 2034, with CAGR of 18% During 2024-2034 [Yahoo! Finance]Yahoo! Finance
- Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Regulus Therapeutics Inc. (NASDAQ: RGLS) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Regulus Therapeutics Inc. (NASDAQ: RGLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
RGLS
Earnings
- 11/9/23 - Miss
RGLS
Sec Filings
- 4/22/24 - Form EFFECT
- 4/19/24 - Form ARS
- 4/19/24 - Form DEF
- RGLS's page on the SEC website